BioSpace News Archive

Dyadic International, Inc. announced that the Company’s CEO Mark Emalfarb will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis New York City February 14th -15th, and virtually through the 17th.

Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference on Wednesday, February 9, 2022, at 9:30 a.m. ET and will participate in one-on-one meetings during the conference.

GBS Inc. today announced that it will release its financial results for the second quarter ended December 31, 2021, shortly after the NASDAQ market close on Thursday, February 10.

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N. Newcomer, M.D., to its Board of Directors effective February 2, 2022.

Check-Cap Ltd. today announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for its amended Investigational Device Exemption (IDE) application, enabling initiation of the U.S. pivotal study.

Pneumoconiosis—a spectrum of lung disorders caused by inhalation of mineral dust particles—is unfortunately a common occupational hazard for people who work in mines and chemical industries.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Erik Harris has joined the Board of Directors.

Bio Products Laboratory issues an update on its financial results and operational highlights for the 12 months ended 31 December 2021, including the more recent developments since first half trading update issued in July.

Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, is proud to present Dr. Volker W. Stieber, MD, as a welcome addition to its distinguished Neuro-Oncology Advisory Board.

According to Emergen Research, the global diabetic care market size was USD 22.70 billion in 2019 and is expected to reach USD 41.71 billion in 2027 and register a revenue CAGR of 7.9% during the forecast period, 2021-2028.